Clinical study on external counterpulsation in treatment of viral hepatitis

Table 1 General data

Type	ECP Group				Control Group
	n	Age	m	f	n	Age	m	f
IHA	309	30.4 ± 8.5	200	109	205	30.9 ± 8.7	129	76
IHB	270	30.0 ± 6.6	164	106	187	31.2 ± 8.1	104	83
NIHA	97	31.8 ± 8.9	59	38	102	29.9 ± 9.1	57	45
NIHB	98	29.5 ± 6.2	62	36	104	30.9 ± 7.0	64	40
CPH	190	30.6 ± 6.2	135	55	147	33.4 ± 10.1	103	40
CHA	40	32.1 ± 5.7	30	10	38	37.4 ± 12.4	27	11
TOTAL	1004	30.7 ± 7.0	650	354	783	32.3 ± 9.2	484	299

I: Ictero, NI: No ictero, n: Number, m: Male, f: Female.

Table 2 Extinction of symptoms after 2 weeks of external counterpulsation treatment

Type	Acratia	Anorexia	Nausea	Sleeplessness
ECP group	82.93 (%)a	86.04 (%)a	82.58 (%)a	94.50 (%)a
Control group	53.12 (%)	67.43 (%)	62.25 (%)	25.78 (%)

^aP < 0.05 vs control group. ECP: External counterpulsation.

Table 3 Effective rate comparison among group

	ECP Group									Control Group
	N	Notably		Effective		Improved		Ineffective		N	Notably		Effective		Improved		Ineffective
		n	%	n	%	n	%	n	%		n	%	n	%	n	%	n	%
IHA	300	182	58.8	96	31.1	25	8.1	6	1.9	205	30	14.6	73	35.7	65	31.7	37	18.0
IHB	270	129	47.8	103	38.1	23	8.5	15	5.6	137	24	12.8	75	40.1	57	30.5	31	16.6
NIHA	96	51	52.6	34	35.1	8	8.2	4	4.1	102	26	25.5	32	31.4	31	30.1	13	12.7
NIHB	98	37	37.8	39	39.8	12	12.2	10	10.2	104	25	24.0	35	33.7	28	26.9	16	15.4
CPH	190	76	40.0	70	36.8	36	18.9	8	4.3	147	36	24.5	43	29.3	49	33.3	19	12.9
CAH	40	4	10.0	19	47.5	10	25.0	7	17.5	38	6	15.8	8	21.1	15	39.5	9	26.7
TPTAL	1004	479	47.7	361	35.9	14	11.4	5	5.1	783	147	18.8	266	34.0	245	31.3	125	16.0

^bP < 0.01 vs control group. I: Ictero; NI: No ictero; ECP: External counterpulsation.